Floatz logo

Human Cd19 Targeted T Cells

Diffuse Large B-cell Lymphoma

Hrain Biotechnology Co., Ltd.Cell therapyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

271 Active assets in the Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Human Cd19 Targeted T Cells is also rated in:

Advanced CancersDormant
CC
Indicative ·
47 / 100
View asset →
LeukemiaDormant
CC
Indicative ·
44 / 100
View asset →
Blood And Marrow TransplantationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →